Navigation Links
Naviscan Receives CE Mark Approval for High-Resolution Breast PET and PET-Guided Biopsy
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Naviscan, the leader in organ-specific molecular imaging, announced today that it obtained CE Mark approval for both its high-resolution PET scanner and PET-guided biopsy accessory.  The breast application of the scanner is Positron Emission Mammography (PEM).  Naviscan has expanded its distribution into 13 European countries and has already received its first two orders in Germany and Switzerland.

Naviscan manufactures the only commercially-available, high-resolution PET scanner with PET-guided biopsy system.  The scanner uses PET technology to produce tomographic images that allow physicians to visualize breast tumors with an unprecedented resolution of 1.6 mm, about the width of a grain of rice.  In recently published data, PEM has been found to be significantly more precise than existing technologies at identifying benign and cancerous lesions, in what scientists call "specificity," therefore reducing the number of unnecessary biopsies.  This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma and cost associated with unnecessary procedures.

"CE Mark approval for Naviscan’s technology is a significant accomplishment and we are thrilled that women in Europe can now benefit from our 3-D, high-resolution, molecular breast imaging (MBI) system," stated Paul Mirabella, Chairman and CEO of Naviscan.  "We look forward to continuing to help detect and treat breast cancer on an even greater global scale."

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain both FDA-clearance and CE Mark approval for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com

For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) at http://pitch.pe/171427


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng
2. Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
3. Naviscan Announces European Launch of Positron Emission Mammography
4. Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development
5. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
6. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
7. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
8. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
9. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
10. MedShape Solutions, Inc. Receives SBIR Phase I Development Grant for Shape Memory Meniscal Repair Device
11. NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on ... the second quarter ended June 30, 2017. ... to date: Continued ... lead project, BL-8040: Announced plans to ... stem cell mobilization treatment for autologous bone-marrow transplantation in ...
Breaking Medicine Technology:
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Yesterday, the ... KKK by saying there are two sides. There are not two sides to hatred, ... to rationalize violence and prejudice, and the NPEIV stands against all forms of such ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: A Story ... parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of Love” is ... Island, New York. , Published by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s ...
(Date:8/18/2017)... (PRWEB) , ... ... ... For Immediate ... Polling Shows Young Women Seek Sex and Relationship Advice from ...
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, 2017 — ... advocating for active, healthy lifestyles and highlighting the importance of proactive eye and ... impairments and shares the latest innovations in hearing aid technology. , According ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, ... new charity drive to generate community support for efforts to educate the local population ... treatments for all types of cancer. , Each day in America, roughly 4,600 ...
Breaking Medicine News(10 mins):